PubMed Health⌕ Search

Biomedical subjects

W Lasoń

Publications and source records attributed to W Lasoń.

At least 73 records · Page 4Linked to original sources

The influence of conditioned fear-induced stress on the opioid systems in the rat.

In this study the rats were repeatedly placed in a conditioning box, and 30 min later were subjected to a mild foot-shock. Anticipation of painful stimuli resulted in development of antinociception before a painful stimulus was applied. This conditioned fear-induced antinociception was antagonized by naloxone (1 mg/kg IP), as well as by ipsapirone (10 mg/kg IP), as measured by a tail-flick test. Stressed rats were hypersensitive to the analgesic action of morphine (1 mg/kg SC), but not to the specific kappa agonist U69,593 (0.1 mg/kg SC). In order to determine the involvement of the proopiomelanocortin and prodynorphin systems in stress we measured levels of their represenative peptides beta-endorphin and alpha-neoendorphin using selective RIAs. Biochemical data showed that conditioned stress evoked a marked decrease in the beta-endorphin level in the hypothalamus and both lobes of the pituitary, together with a three-fold increase in the peptide level in the plasma. In contrast, the level of alpha-neoendorphin in the hypothalamus, pituitary and spinal cord remained unchanged. Only in the plasma a decrease in that peptide content was found. Furthermore, in vitro studies showed that the spontaneous and K(+)-stimulated release of beta-endorphin from the hypothalamus of rats which had been exposed to a conditioned stimulus was enhanced, whereas the release of alpha-neoendorphin from that tissue was attenuated. These results suggest a major role of the proopiomelanocortin system and, to the lesser extent, of the prodynorphin one in the mechanism of a conditioned fear-induced stress.

Analgesia↗

Modulation of prodynorphin peptides release from the rat spinal cord in vitro.

The release of immunoreactive (ir-) dynorphin (DYN) and alpha-neoendorphin (alpha-NEO) from spinal cord slices was investigated in rats. A stable, spontaneous, in vitro release of these peptides (6.7 +/- 0.3 of ir-DYN and 15.5 +/- 0.3 fmol/min/g wet tissue of ir-alpha-NEO) was measured in superfusates using highly sensitive radioimmunoassays. The exposure of the slices to the superfusion medium containing 57 mM K+ or 50 microM veratridine increased circa three times the basal release of the peptides. The K(+)-evoked release of ir-alpha-NEO was Ca2(+)-dependent, and the veratridine stimulation was abolished by 1 microM tetrodotoxin. Modulation of the alpha-neoendorphin release from the lumbar enlargement of the rat spinal cord by various neuroactive compounds was studied in vitro. Noradrenaline (1 microM) slightly enhanced the K(+)-induced release of ir-alpha-NEO, but was without effect on the basal release. On the other hand, GABA (10 microM) and muscimol (1 microM) inhibited the K(+)-stimulated release of the peptide. The effect of muscimol was attenuated by bicuculline (10 microM). Other compounds, such as serotonin (1 microM), naloxone (1 microM), U-50, 488H and bicuculline, altered neither the basal nor the K(+)-induced release. These data indicate that both ir-DYN and ir-alpha-NEO are stored in a releasable pool in the spinal cord, which supports the concept that prodynorphin peptides can serve as neurotransmitters in this structure. Furthermore, this study suggests that the spinal cord prodynorphin system may be under an inhibitory gabaergic and an excitatory catecholaminergic control.

Animals↗

The influence of chronic stress on multiple opioid peptide systems in the rat: pronounced effects upon dynorphin in spinal cord.

Recurrent exposure to intermittent electrical foot-shock (30 min, twice daily) for 7 days caused an increase in immunoreactive (ir) dynorphin and ir-alpha-neo-endorphin in lumbar and cervical (but not thoracic) spinal cord as measured 16 h following the final session. At this time the level of ir-Met-enkephalin-Arg6-Gly7-Leu8 (MEAGL) was also increased at the lumbar level. An acute foot-shock depleted spinal cord dynorphin in chronically stressed but not in naive rats. No alterations in levels of ir-dynorphin or ir-MEAGL were seen in discrete brain tissues. In contrast to the brain, where no effects were seen, the levels of beta-endorphin increased in both lobes of the pituitary. This change, however, was not accompanied by an alteration in levels of beta-endorphin in plasma. These data show that chronic foot-shock stress selectively influences particular pools of opioid peptides, predominantly those derived from proenkephalin B in the spinal cord and from proopiomelanocortin in the anterior pituitary. It is suggested that alterations observed in the spinal cord reflect enhanced activity of the proenkephalin B system in response to chronic nociceptive stimulation.

Animals↗

Single and repeated electroconvulsive shock differentially affects the prodynorphin and pro-opiomelanocortin system in the rat.

The effects of single and repeated maximal electroconvulsive shock (ECS, 150 mA, 50 Hz, 0.5 s) on the immunoreactive (ir-) dynorphin and beta-endorphin level in the rat brain, spinal cord and pituitary were studied. A single ECS induced a transient decrease in the hypothalamic ir-dynorphin, but did not influence the peptide content in the spinal cord, hippocampus and neurointermediate lobe of the pituitary. In contrast, the single ECS only slightly decreased the ir-beta-endorphin level in the hypothalamus, but caused a considerable fall in the peptide content in both lobes of the pituitary. A repeated ECS (every day for 9 days and 3 times a week for 3 weeks) markedly increased the ir-dynorphin content in the hypothalamus by 28 and 56%, respectively. Irrespective of the paradigm used, the repeated ECS strongly influenced spinal dynorphin neurons. At the beginning of our experiment (ECS applied 3 times) a fall in the peptide levels could be observed, but a longer treatment (ECS applied 9 times) led to its enhancement. The repeated ECS also induced a gradual decrease in the hippocampal ir-dynorphin level, followed by a long-term, rebound increase. In contrast to those numerous changes evoked in the dynorphin system, the repeated ECS did not evoke any changes in the hypothalamic and pituitary ir-beta-endorphin levels. As shown in the behavioral experiment, an acute ECS treatment resulted in a moderate increase in the pain threshold, measured by tail-flick and hot-plate tests. A prolonged ECS administration (3, 6 and 9 times) markedly enhanced the ECS-induced analgesia and catalepsy.(ABSTRACT TRUNCATED AT 250 WORDS)

Analgesia↗

Involvement of endogenous opioid peptides in fenfluramine anorexia.

The effect of chronic fenfluramine (20 mg/kg, once daily) injections on the brain and peripheral immunoreactive (ir) dynorphin (DYN), alpha-neoendorphin (ANEO) and beta-endorphin (BE) was studied in rats. Fenfluramine injected repeatedly for 5 and 9 days induced anorexia. In the same animals there were no significant changes in the ir-DYN and ir-ANEO contents in the brain and pituitary. However, the ir-DYN and ir-ANEO contents in the gastrointestinal tract (duodenum) were markedly decreased after 5 and 9 days of fenfluramine injection. In contrast to ir-DYN and ir-ANEO, there was an increase in the hypothalamic and a decrease in the anterior lobe of pituitary ir-BE content. There was no significant change in the neurointermediate (NI) lobe of the pituitary. The results of our study suggest that part of the fenfluramine anorexia may be mediated by the peripheral prodynorphin and central beta-endorphin systems.

Animals↗

Brain and peripheral opioid peptides after changes in ingestive behavior.

The levels of dynorphin, alpha-neoendorphin and beta-endorphin immunoreactivity (ir-DYN, ir-alpha-NEO, ir-beta-E) were measured in the brain, pituitary and gut of rats subjected to a variety of manipulations. Water deprivation caused an increase in the ir-DYN and ir-alpha-NEO content in the hypothalamus and a decrease in the neurointermediate (NI) lobe of the pituitary. The ir-beta-E level decreased in the hypothalamus and anterior lobe of the pituitary, while it increased in the NI-pituitary. Food deprivation, as well as chronic fenfluramine (10-20 mg/kg) treatment increased, while acute muscimol (0.5 micrograms/10 microliter) treatment decreased the ir-beta-E, but not ir-DYN or ir-alpha-NEO content in the hypothalamus. The anterior pituitary content of ir-beta-E was increased after food deprivation and decreased after chronic fenfluramine treatment. However, the ir-DYN and ir-alpha-NEO contents in the duodenum were markedly increased after food deprivation, while chronic fenfluramine treatment led to a dramatic decrease in the ir-DYN content. These results suggest that the levels of opioid peptides in the brain, pituitary and gut may be differentially and independently affected by alteration of the ingestive behavior.

Animals↗

Release of opioid peptides from the spinal cord of rats subjected to chronic pain.

Chronic localized pain increased the level of the opioid peptides, dynorphin (DYN), alpha-neoendorphin (ANEO), Met-enkephalin (MET) and Mets-enkephalin-Arg6-Gly7-Leu8 (MEAGL), in the lumbar enlargement of the rat spinal cord. It was accompanied with a reduction of the spontaneous and K+-stimulated release of ANEO and MEAGL from spinal cord slices in vitro and a decreased release of ANEO from the spinal cord in vivo. The results indicate that the reduction in the activity of endogenous opioid peptide systems might occur in the spinal cord of rats subjected to chronic pain.

Animals↗

Differential regulation of the brain and gut immunoreactive dynorphin by the serotonin system.

Administration of drugs such as fenfluramine, 20-40 mg/kg, and m-chlorophenylpiperazine (m-CPP), 2.5-5 mg/kg, which release serotonin or activate postsynaptic serotonin receptors, respectively, induced a dramatic decrease in the duodenal content of immunoreactive dynorphin (ir-DYN). The effect was antagonized by cyproheptadine, 1 mg/kg. Similarly, acute administration of the specific serotonin reuptake blockers fluvoxamine, 15 mg/kg, or femoxetine, 10 mg/kg, and 5-hydroxytryptophan (5-HTP), 40-160 mg/kg, evoked a marked decrease in the duodenal content of ir-DYN. A combined administration of fluvoxamine or femoxetine and 5-HTP failed to potentiate the effect of individual treatment. Only a higher dose of fenfluramine, 40 mg/kg, increased the ir-DYN content in the hypothalamus. These results suggest that the brain and gut ir-DYN is independently regulated by the serotonin system and that a serotonin mechanism might stimulate release of the gut dynorphin content.

5-Hydroxytryptophan↗

Antidepressants and endogenous opioid peptide systems.

The influence of antidepressants on the brain and pituitary content of immunoreactive beta-endorphin (ir-beta E) and dynorphin (ir-DYN) was studied in rats. Chronic administration of the first and second generation antidepressants imipramine, citalopram and rolipram, and of the antidepressant neuroleptics levomepromazine and chlorprothixene elevated the level of ir-beta E in the hypothalamus. Imipramine and levomepromazine also increased the level of ir-DYN in this tissue. Imipramine administered chronically potentiated stress-induced as well as morphine analgesia. The results obtained suggest that chronic antidepressants enhance the brain opioid system activity and increase the sensitivity of opiate receptors.

Animals↗

The effect of various opiate receptor agonists on the seizure threshold in the rat. Is dynorphin an endogenous anticonvulsant?

The effects of various opiate receptor agonists on the seizure threshold after an intravenous infusion of pentylenetetrazol were investigated in rats. The mu- and epsilon-receptor agonists, morphine (20-40 micrograms) and beta-endorphin (5-10 micrograms) show proconvulsant properties towards clonic and tonic seizures. The delta-receptor agonist (D-Ala2,D-Leu5-enkephalin, DADL 5-40 micrograms) and alpha-neoendorphin (20-40 micrograms) show pro- and anticonvulsant properties towards clonic and tonic seizures, respectively. Anticonvulsant properties of DADL are possibly due to its action on the spinal cord, since after the intrathecal injection this effect is still observed. Similarities between DADL and alpha-neoendorphin suggest that they may act through the same receptor. The kappa-receptor agonist dynorphin A (5-20 micrograms) and its degradation-resistant analogue D-Arg-dynorphin1-13 (10 micrograms) show significant anticonvulsant properties. Our present results suggest that the kappa-receptor agonist dynorphin may act physiologically as an endogenous anticonvulsant, in contrast to other opioid peptides.

Animals↗

The effect of gamma-hydroxybutyrate and anticonvulsants on opioid peptide content in the rat brain.

Gamma-hydroxybutyrate administered in anaesthetic doses produced a profound increase in the levels of dynorphin A (DYN) in the hippocampus and pituitary. Simultaneously, a significant, short-lasting decrease in beta-endorphin (B-E) levels occurred in the brain and pituitary. Antiepileptic drugs strongly, though in various ways, influenced the brain DYN and B-E concentrations; though most of them caused a decrease in the hypothalamic opioid peptide content.

Animals↗

Opioid peptides, particularly dynorphin, after amygdaloid-kindled seizures.

The influence of amygdaloid kindling on brain and pituitary content of immunoreactive dynorphin (IR-DYN) and other opioid peptides was studied in rabbits. The kindling was very effective in increasing the hippocampal levels of IR-DYN, alpha-neoendorphin and Leu-enkephalin, but remained without any significant effect on the levels of IR-DYN and beta-endorphin in the majority of brain structures studied. The concentration of IR-DYN in the hippocampus remained at the control level throughout the development but was increased dramatically after completion of kindling. Biochemical alterations persisted for at least one month following the completion of kindling. The obtained results suggest that the hippocampal IR-DYN and related peptides may play some role in the maintenance of amygdaloid-kindled seizures.

Amygdala↗

Effect of neurosteroids on glutamate binding sites and glutamate uptake in rat hippocampus.

Effects of some neurosteroids on the binding of [3H]-glutamate, [3H]-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and [3H]-MK-801, as well as on the [3H]-glutamate uptake were examined in rat hippocampus. The following compounds were evaluated: (a) positive modulators of the GABA(A) receptor: 5alpha-pregnan-3alpha-ol-20-one (allopregnanolone), 5alpha-pregnane-3alpha,21-diol-20-one (allotetrahydrodeoxycorticosterone), 5alpha-pregnan-3alpha-ol-11,20-dione (alphaxalone) and 5alpha-androstan-3alpha-ol-17-one (androsterone); (b) compounds showing GABA(A)-antagonistic and/or N-methyl-D-aspartic acid (NMDA)-agonistic properties: dehydroepiandrosterone sulfate and pregnenolone sulfate; (c) a substance which, apart from its GABA(A)-agonistic potency, has a NMDA-antagonistic action: 5beta-pregnan-3alpha-ol-20-one. None of those neurosteroids tested at concentrations of 0.001-100 microM affected the binding of [3H]-glutamate, [3H]-AMPA and [3H]-MK-801 or the glutamate uptake. The present study suggests that the previously reported inhibitory effects of neurosteroids on excitatory amino acid-induced seizures and neurotoxicity can be linked neither to the direct interaction of these compounds with the above binding sites on glutamate receptor complexes, nor to the glutamate uptake mechanism.

Animals↗

Allopregnanolone attenuates kainate-induced toxicity in primary cortical neurons and PC12 neuronal cells.

In this study, we demonstrated that allopregnanolone at 500 and 1000 nM significantly inhibited kainate-induced lactate dehydrogenase release from primary cortical cells by ca. 25 and 50%, respectively. Furthermore, allopregnanolone doses of 100 and 500 nM decreased cytotoxic effects of kainate (150 microM, 24-hour exposure) in PC12 neuronal cells by about 55 and 37%, respectively. These data strongly support neuroprotective effects of allopregnanolone observed in vivo.

Animals↗